PUBLISHER: DelveInsight | PRODUCT CODE: 1259771
PUBLISHER: DelveInsight | PRODUCT CODE: 1259771
Key Highlights:
DelveInsight's "Smoking Cessation and Nicotine Addiction- Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the smoking cessation and nicotine addiction, historical and forecasted epidemiology as well as the smoking cessation and nicotine addiction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Smoking cessation and nicotine addiction market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM smoking cessation and nicotine addiction market size from 2019 to 2032. The report also covers current smoking cessation and nicotine addiction treatment practice/algorithm and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
Smoking Cessation and Nicotine Addiction Overview
Nicotine/tobacco dependence is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated tobacco use and that typically include a strong desire to use tobacco, difficulties in controlling its use, persistence in tobacco use despite harmful consequences, a higher priority given to tobacco use than other activities and obligations, increased tolerance and sometimes a physical withdrawal state.
Repeated exposure to nicotine develops neuro adaptation of the receptors, resulting in tolerance to many of the effects of nicotine. Withdrawal symptoms appear on stoppage of tobacco use, characterized by irritability, anxiety, increased eating, dysphoria, and hedonic dysregulation, among others. Smoking is also reinforced by conditioning.
Smoking Cessation and Nicotine Addiction Diagnosis
Metabolites of nicotine such as cotinine, nor nicotine, and anabases can be detected in urine and blood; these tests can test compliance with withdrawal therapy or nicotine toxicity. Another method to assess nicotine is COa level; this method is related to cotinine. Some questionnaires can measure nicotine dependence, such as the Fagerstrom Test for Nicotine Dependence, the Wisconsin Inventory of Smoking Dependence and Motives, and the Smokeless Tobacco Dependence Scale.
Further details related to country-based based variations are provided in the reported
Smoking Cessation and Nicotine Addiction Treatment
Quitting smoking for good and overcoming nicotine dependence requires a multi-faceted approach that may include counseling, support groups, behavioral therapy, and medication. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy as well as bupropion and varenicline.
Many molecules are in the pipeline to treat nicotine addiction patients across the 7MM to cater to their needs. Some major products are anticipated hit the market during 2019-2032, including cytisinicline, AXS-05, and CX-101.
As the market is derived using patient based model, the smoking cessation and nicotine addiction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Prevalent Cases of Tobacco Use, Gender-specific Prevalent Cases of Tobacco Use, Prevalent Cases of Tobacco Use by Product Type, Age-specific Prevalent Cases of Tobacco Use, Prevalent Nicotine Dependent Cases Among Cigarette Smokers, and Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), and the UK, and Japan from 2019 to 2032. The total prevalent cases of tobacco use in the 7MM comprised of approximately 137,010 thousand cases in 2022 and are projected to decrease during the forecasted period (2023-2032).
Drug chapter segment of the smoking cessation and nicotine addiction report encloses the detailed analysis of smoking cessation and nicotine addiction marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the smoking cessation and nicotine addiction clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Emerging Drugs
Cytisinicline (cytisine): Achieve Life Sciences
Cytisinicline (cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment approved and marketed in Central and Eastern Europe for over 20 years.
Cytisinicline has completed a Phase III study, evaluating the efficacy and safety of 3 mg cytisinicline thrice a day for a treatment duration of 42 days/6 weeks in adult smokers cytisinicline. In addition to this trial, the company is conducting another Phase III study, ORCA-3, and topline data results are expected to be reported in the second quarter of 2023 to empower their findings. Achieve Life Sciences is also evaluating cytisinicline in Phase II for the e-cigarette user population and expects to announce the results by the second quarter of 2023.
Note: Detailed emerging therapies assessment will be provided in the final report.
Drug Class Insights
The treatment for nicotine addiction and smoking cessation includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.
Pharmacotherapy acts synergistically with behavioral counseling to increase quit rates and should be encouraged for virtually all daily smokers and considered on a case-by-case basis for nondaily smokers. The US FDA has approved five nicotine replacement therapy (NRT) products as well as bupropion and varenicline for smoking cessation.
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. Several distinct products and services are available today for smoking cessation, alongside smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.
The US FDA has approved two smoking cessation products that do not contain nicotine. They are CHANTIX (varenicline tartrate), and ZYBAN (bupropion hydrochloride). Both products are available in tablet form and by prescription only. In the past years, the generic of both the approved drug has entered the market. Both are widely available in the US and the European market. In Japan, varenicline (CHAMPIX), NRT, and some off-label therapies are used for smoking cessation. Bupropion-SR is not licensed in Japan for smoking cessation.
Key players such as Achieve Life Sciences (Cytisinicline), Axsome Therapeutics (AXS-05), and NFL Biosciences (NFL-101) and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of smoking cessation and nicotine addiction.
This section focuses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. For example, for cytisinicline, we expect the drug uptake to be slow medium with a probability-adjusted peak share of 18%, years to peak is expected to be 7 years from the year of launch.
Further detailed analysis of emerging therapies drug uptake in the report…
Smoking Cessation and Nicotine Addiction Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for smoking cessation and nicotine addiction emerging therapies.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on smoking cessation and nicotine addiction evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, drug uptake along with challenges related to accessibility, include Medical/scientific writers, Medical Professors, Industry experts and Others.
DelveInsight's analysts connected with 50+ KOLs to gather insights, however interviews were conducted with 15+ KOLs in the 7MM. Centers such as Washington University School of Medicine, Spanish Society of Family and Community Medicine, University Hospital Heidelberg, etc. were contacted. Their opinion helps to understand and validate current and emerging therapies treatment patterns or smoking cessation and nicotine addiction market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, and patient burden, and competitive landscape, cost-effectiveness and geographical accessibility of therapies are provided. These pointers are based on Analyst's discretion and assessment of the patient burden, cost analysis and existing and evolving treatment landscape.
Conjoint Analysis is done to analyze multiple approved and emerging therapies on the basis of relevant attributes such as safety, efficacy, and frequency of administration, route of administration and order of entry. Scoring is given based on these parameters to analyze the effectiveness of a therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated, for instance, in smoking cessation and nicotine addiction trials, one of the most important primary outcome measure is the proportion of participants with smoking abstinence.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability and the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
In the US, treatments for tobacco use and dependence can be covered through health insurance, which includes coverage through private insurance (both the individual market and the employer markets), Medicaid, or Medicare, or coverage provided to active-duty military and veterans; and/or employer-based wellness programs that may be offered in conjunction with health insurance. Comprehensive coverage of tobacco cessation treatments includes coverage of evidence-based cessation treatments (individual, group, and telephone counseling) and FDA-approved cessation medications.
The report further provides the detailed insights on the country wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out of pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs etc.
Key Questions
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs and Emerging Therapies: